Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Manogepix SCHEMBL510522 | 1.00 | NPC1 (0.41) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL30518388 | 1.00 | NPC1 (0.41) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL1323608 | 0.99 | NPC1 (0.41) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL1323256 | 0.99 | NPC1 (0.41) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL1322997 | 0.99 | NPC1 (0.41) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL1322796 | 0.99 | NPC1 (0.41) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL1323272 | 0.94 | NPC1 (0.37) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL1322795 | 0.94 | NPC1 (0.37) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL1323004 | 0.92 | CDC7 (0.36) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A | |
| Manogepix SCHEMBL3468507 | 0.92 | CDC7 (0.38) | NPC1ALDH1A1CYP2C19CYP2D6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638448-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | claimed |
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-12-26 | — | — | US | claimed |
| EP-4419531-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2024-08-28 | — | — | EP | claimed |
| WO-2024130408-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | claimed |
| WO-2023065014-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2023-04-27 | — | — | WO | claimed |
| EP-4638448-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | disclosed |
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| CN-118806911-A | Use of Fosmanogepix in the treatment of mycobacterial infections in Kansas | 首都医科大学附属北京胸科医院 | 2024-10-22 | — | — | CN | disclosed |
| EP-4419531-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024130408-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023065014-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | NPC1 63/4885ALDH1A1 596/4885CYP2C19 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.